Can Ekinci

About us

Together, we will keep fighting for better treatments and access for everyone with Duchenne.

Powered by Hostinger

Latest Articles

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Press Releases October 5, 2026 0

Capricor Therapeutics has reported new results from the HOPE-3...

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Press Releases October 4, 2026 0

Ractigen Therapeutics has presented positive first-in-human data for RAG-18...

Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data

Press Releases October 3, 2026 0

Entrada Therapeutics’ ENTR-601-44 is an investigational therapy designed for...

Frequently Asked Questions About Elevidys Used for DMD

Approved Therapies August 21, 2026 0

Duchenne muscular dystrophy (DMD) is a genetic condition that...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 0

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 0

The duchenne muscular dystrophy treatment cost has become one...

Duchenne MD

Genetic

Care Guidelines

Health Guidelines

Latest Posts

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data

Latest Posts

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data

NS Pharma’s Brogidirsen Shows 5-Year Clinical Data in DMD Patients Amenable to Exon 44 Skipping

Don't Miss

GEN6050X Exon 50 Skipping Base Editing Drug: One-Year Results Show Encouraging Progress for Duchenne Muscular Dystrophy

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)

Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus

About us

Latest Articles

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Entrada Therapeutics’ ENTR-601-44 Shows Dose-Dependent Exon 44 Skipping in Early PK/PD Data

Most Popular

Frequently Asked Questions About Elevidys Used for DMD

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control